Strategic options Selvita has just reported Q1 2026 results and is launching a strategic options review, signaling openness to partnerships, divestitures, or collaboration opportunities that could expand service scope or enter new markets.

Preclinical leadership As one of Europe’s largest preclinical CROs with a bridging mission to early drug discovery and clinical development, Selvita presents a compelling partner for pharma companies seeking end-to-end research services and scalable collaboration models.

Financial scale Annual revenue in the mid tens of millions range positions Selvita as a mid-sized partner with potentially flexible pricing, faster decision cycles, and the ability to tailor engagement models for mid-to-large projects.

Tech enablement Adoption of modern tech stacks including Kubernetes, Azure, and collaboration tools suggests strong digital infrastructure for secure data handling, cloud-based workflows, and scalable project delivery that can appeal to data-intensive programs.

European footprint Strong regional presence in Europe combined with a broad CRO landscape signals opportunities for co-development, regional regulatory-compliant studies, and strategic alliances with companies seeking European execution capabilities.